January 2023 in “National Journal of Physiology, Pharmacy and Pharmacology” Tofacitinib effectively reduced hair loss in alopecia areata patients without adverse effects.
October 2025 in “Frontiers in Toxicology” A new method effectively predicts estrogen-related health effects for early screening.
55 citations
,
March 1990 in “The Journal of Clinical Endocrinology and Metabolism” Finasteride may treat baldness but less effective for those with 5α-reductase deficiency.
13 citations
,
September 2011 in “International Urology and Nephrology” 111 citations
,
June 2015 in “Age and Ageing” Dutasteride, fesoterodine, and finasteride are beneficial for older patients, while most other drugs should be used cautiously or avoided.
June 2024 in “Journal of Clinical Oncology” The combination of TACE and Donafenib is effective and tolerable for treating unresectable liver cancer.
July 2023 in “World Journal of Biology Pharmacy and Health Sciences” Trazodone and Chlorpromazine might help treat sexual dysfunction from finasteride and SSRIs.
September 2002 in “Oncology Times” Promising cancer treatments were found, but the manufacturer closed.
35 citations
,
June 2018 in “Urology” The review suggests younger men taking 1 mg finasteride report more side effects, including sexual, skin, metabolic, and psychological issues.
November 2023 in “Indian Dermatology Online Journal” Tofacitinib was effective for severe, treatment-resistant hair loss without side effects.
46 citations
,
February 2012 in “Oncology Reports” Sorafenib helps some advanced cancers alone or with other treatments, but not all, and research continues to improve its use.
2 citations
,
January 2025 in “Сибирский научный медицинский журнал” TS-13 effectively stops tumor growth and reduces chemotherapy side effects.
1 citations
,
October 2022 in “Iet Nanobiotechnology” The dutasteride nanoemulsion could improve hair loss treatment by enhancing drug penetration and retention in hair follicles.
7 citations
,
September 2024 in “The Journal of Dermatology” Ritlecitinib helps regrow hair in people with alopecia totalis and universalis and is safe to use.
March 2023 in “PARIPEX INDIAN JOURNAL OF RESEARCH” Tofacitinib helped regrow hair in most patients with severe hair loss.
84 citations
,
August 2023 in “Drugs” Ritlecitinib is approved in the USA and Japan for treating severe hair loss in people aged 12 and older.
October 2020 in “Journal of Pharmaceutical Sciences” Topical finasteride with EGCG or TA improves drug release and dermal uptake, potentially treating hair loss effectively.
February 2016 in “Journal of urology and nephrology open access” Finasteride, a drug that prevents testosterone conversion, can effectively reduce blood loss in prostate surgery, especially for patients with a prostatic volume over 30 cc, and decrease post-surgery complications.
133 citations
,
July 2006 in “International Journal of Dermatology” The cream effectively and safely reduces facial hair in women.
11 citations
,
December 2010 in “The Journal of Urology” Taking oral testosterone with or without dutasteride increases testosterone levels and could be an effective treatment for low testosterone.
April 2013 in “The FASEB Journal” Dutasteride showed some prevention of prostate issues but also had limitations, especially with high-grade tumors.
January 2018 in “Surgical and Cosmetic Dermatology” Finasteride and dutasteride are effective for male hair loss and enlarged prostate but may cause reversible sexual side effects.
January 1975 in “NJEA Review” The drug showed promise in treating renal cell carcinoma with manageable side effects.
January 2025 in “Journal of Crohn s and Colitis” Tofacitinib is effective and safe for elderly patients with ulcerative colitis.
27 citations
,
July 2009 in “Experimental and Clinical Endocrinology & Diabetes” Finasteride safely reduces excessive hair growth in women.
6 citations
,
June 2014 in “PubMed” Combining TUSV with finasteride effectively treats recurrent hemospermia.
February 2024 in “The Journal of Sexual Medicine” 5-α reductase inhibitors do not significantly affect male reproductive function but may reduce semen volume.
9 citations
,
October 2019 in “Dermatologic Therapy” Oral tofacitinib has a moderate success rate and is generally safe for treating hair loss in some patients.
115 citations
,
January 2001 in “American journal of clinical dermatology” Eflornithine cream effectively reduces women's unwanted facial hair but hair returns if treatment stops.
111 citations
,
August 2002 in “Journal of Medicinal Chemistry” New compounds were made that block an enzyme linked to breast cancer better than existing treatments.